Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALE.P03 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ALE.P03, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALE.P03 | ALEP03|ALE P03 | Limited information is currently available on ALE.P03, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07169734 | Phase Ib/II | ALE.P03 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Recruiting | USA | NLD | ITA | FRA | ESP | 3 |